BioLight Inks Agreement With Alexion To Explore Technology For Diagnosis Of Retinal Diseases
(RTTNews) - BioLight Life Sciences Ltd. announced Tuesday it has signed a research collaboration agreement with Alexion Pharmaceuticals, Inc. (ALXN), a subsidiary of AstraZeneca plc (AZN, AZN.L), focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases.
The study, financed by Alexion and BioLight, will evaluate a screening technique that analyzes components of the tear film, an outer eye surface fluid layer. The Technology was licensed from Harvard University and will be utilized to analyze tear samples.
The study will be conducted at the Tel Aviv Medical Center and led by Prof. Anat Loewenstein, Chair of the Ophthalmology department.
read more
Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris
The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major AstraZeneca's Rare Disease unit Alexion Pharmaceuticals, to treat certain rare diseases. Soliris is a medicine used to treat adults and children with paroxysmal nocturnal haemoglobinuria or PNH...
RTTNews
|
Před 173 dny
Amazon, Microsoft, Pfizer To Invest Billions In French Projects
Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews
|
Před 190 dny
AstraZeneca To Withdraw Its Covid-19 Vaccine Vaxzevria Worldwide
AstraZeneca, a major provider of Covid-19 vaccines across the world mainly during the initial pandemic period, has initiated a process to withdraw its Vaxzevria COVID-19 vaccine worldwide, citing weak demand and the surplus availability of new vaccines. Meanwhile, AstraZeneca reportedly had admitted recently in court documents that the vaccine could cause side-effects such as blood clots...
RTTNews
|
Před 195 dny
AstraZeneca Says AIRSUPRA Now Commercially Available In US As FDA-approved Option For Asthma
AstraZeneca (AZN, AZN.L) announces Monday that AIRSUPRA (albuterol/budesonide) is now commercially available in the US by prescription. AIRSUPRA was approved based on the results from two Phase III trials, MANDALA and DENALI.
RTTNews
|
Před 302 dny
Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial
Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.
RTTNews
|
Před 316 dny
Allorion Therapeutic Inks Agreement With AstraZeneca For EGFR L858R Allosteric Inhibitor Program
Allorion Therapeutics, a US and China-based biotechnology company, on Tuesday entered into an exclusive option and global license agreement with British drug major AstraZeneca plc (AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).
RTTNews
|
Před 321 dny
AstraZeneca Files Legal Challenge To Protect Access To Medicines For Cancer And Rare Diseases
AstraZeneca plc (AZN) said Friday it has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA) to help protect access to medicines for cancer and rare disease patients.
RTTNews
|
Před 452 dny
AstraZeneca Q2 Profit Surges, Signs Gene Therapy Deal With Pfizer; Stock Up
Shares of AstraZeneca Plc were gaining around 4 percent in London trading as well as around 5 percent in pre-market activity on Nasdaq after the British drug major reported Friday significantly higher profit for its second quarter. Top line beat market estimates. Further, the company maintained its outlook for fiscal 2023, expecting growth. In addition, AstraZeneca noted that its Rare Disease ...
RTTNews
|
Před 480 dny
